skip to main content

SGLT2i Expected Glycosuria — ESENeph MCQ

Instant feedback + full explanation. One question, done properly.

EasyChronic Kidney DiseaseSGLT2i Expected GlycosuriaESENeph

A 45-year-old woman with CKD G3a on Dapagliflozin reports that her urine dipstick (done at a pharmacy health check) shows 2+ glucose. She is not diabetic and has a normal fasting glucose. She is concerned. What should she be told?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — This is an expected pharmacological effect of Dapagliflozin (SGLT2i) – it causes glycosuria by design; it does not indicate diabetes

SGLT2 inhibitors work by inhibiting glucose reabsorption in the proximal tubule, causing deliberate glycosuria. This is the mechanism of action, not a side effect. It occurs in both diabetic and non-diabetic patients. Urine dipstick glucose will be positive. This is important to communicate to patients to avoid unnecessary investigation or anxiety. Community pharmacists and GPs should be aware that glycosuria in SGLT2i users does not indicate diabetes.

Reference: KDIGO 2024 – CKD; Dapagliflozin SPC